Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy of Survodutide in Adults with Obesity and Metabolic Dysfunction-Related Steatotic Liver Disease: Results from the SYNCHRONIZE-MASLD Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

  • By

  • Lee M. Kaplan

  • Elena Startseva

  • Carel W. le Roux

  • Sean Wharton

  • Biykem Bozkurt

  • Daniel F. Mazo

  • Jessica von Schlippenbach

  • Sandra González Maldonado

  • Samina Ajaz Hussain

  • Guy W. Neff

  • Yaneicy Gonzalez Rojas

  • Charles Smith

  • Ramy Younes

  • Arun J. Sanyal

  • June 7, 2026

Share

Original Source(s)

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal

  • June 7, 2026

Related Content

Revisional Laparoscopic One Anastomosis Gastric Bypass for Weight Loss Failure after Restrictive Procedures

Efficacy and safety of transoral incisionless fundoplication in non-obese and obese adults: a population-based cohort study from the United States

Sucrose-free low-fat diet induces metabolic dysfunction through gut dysbiosis and colonic inflammation in mice